Clinical Trial Update: Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 neoadjuvant trial evaluating a paclitaxel plus carboplatin and epirubicin regimen in triple-negative breast cancer. The trial status is unknow…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• ELLENCE (Epirubicin hydrochloride)
• Paraplatin (Carboplatin)
• Taxol (paclitaxel)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: UNKNOWN